Skip to main content
TipRanks
Go Ultimate75% OFF

Donald Debethizy Insider Profile

4 Followers

Donald Debethizy, President & CEO, Director at Gyre Therapeutics, holds 798.00 shares in Gyre Therapeutics (Ticker: GYRE). Most recently, Donald Debethizy Bought 798 shares of Gyre Therapeutics on Feb 16, 2012 for an estimated value of $4.07K.

Donald Debethizy's Trading History

GYRE
Gyre Therapeutics
Feb 16, 2012President & CEO, DirectorInformative Buy4.07K$3.50K
GYRE
Insider Shares: 798.00 (<0.01%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Feb 16, 2012Informative Buy$4.07K798$5.10-35.30%
Dec 18, 2009Informative Sell$5.23M237,930$21.97-15.70%
Dec 16, 2009Informative Sell$401.23K17,991$22.30-16.00%
Sep 09, 2009Uninformative Sell$180.22K12,000$15.01―
Sep 01, 2009Uninformative Sell$145.28K10,000$14.52―

You May Also Like

Donald Debethizy insider profile FAQ

What is the percentage of profitable transactions made by Donald Debethizy?
The percentage of profitable transactions made by Donald Debethizy is 0%.
What is the average return per transaction made by Donald Debethizy?
The average return per transaction made by Donald Debethizy is -22.30%.
What stocks does Donald Debethizy hold?
Donald Debethizy holds: GYRE stocks.
What was Donald Debethizy’s latest transaction?
Donald Debethizy’s latest transaction was an Informative Buy of $4.07K.
What was Donald Debethizy's most profitable transaction?
Donald Debethizy’s most profitable transaction was an Informative Sell of GYRE stock on December 18, 2009. The return on the trade was -15.70%.
What is Donald Debethizy's role in Gyre Therapeutics?
Donald Debethizy's role in Gyre Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.